#1 Clinical Trials Search in Europe

T89

T89, also known as Dantonic, is a botanical drug derived from traditional Chinese medicine that has shown potential in treating various conditions. This article explores the ongoing clinical trials investigating T89’s efficacy and safety in treating chronic stable angina, acute mountain sickness, and COVID-19. We’ll examine the drug’s composition, mechanism of action, and the results of several clinical studies.

Table of Contents

What is T89?

T89, also known as Dantonic[1] or Compound Danshen Dripping Pills[2], is a botanical drug derived from traditional Chinese herbal medicine. It is made from the water extracts of two herbs: Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng), with Borneol added to enhance absorption[3]. T89 has been approved for use in several countries, including China, Russia, South Korea, and others, for treating various cardiovascular conditions[1].

What Conditions Does T89 Treat?

T89 is primarily used to treat and prevent the following conditions:

  • Chronic Stable Angina Pectoris: This is a type of chest pain caused by reduced blood flow to the heart, typically occurring during physical activity or stress[4].
  • Acute Mountain Sickness (AMS): A condition that can occur when ascending to high altitudes too quickly, causing symptoms like headache, nausea, and dizziness[5].
  • COVID-19: T89 has been investigated for its potential to improve oxygen saturation and clinical symptoms in patients with COVID-19[6].

How Does T89 Work?

T89 works through several mechanisms to improve cardiovascular health and address the symptoms of its target conditions:

  • Improving blood circulation: T89 helps activate blood circulation and remove blood stasis, which can improve overall cardiovascular function[6].
  • Enhancing oxygen delivery: The drug improves the oxygen-carrying capacity of red blood cells and increases oxygen saturation in the blood[6].
  • Protecting organs: T89 can help reduce damage to major organs like the heart, brain, lung, and kidney caused by hypoxia (low oxygen levels)[6].
  • Improving microcirculation: The drug helps prevent microcirculation disorders by inhibiting the reduction of various blood components and adhesion factors[6].

Clinical Trials and Research

T89 has been the subject of numerous clinical trials to evaluate its safety and efficacy for various conditions:

  • Chronic Stable Angina: Multiple phase II and III trials have been conducted to assess T89’s effectiveness in treating angina symptoms and improving exercise tolerance[1][4].
  • Acute Mountain Sickness: Studies have investigated T89’s potential to prevent and treat AMS symptoms in people ascending to high altitudes[5][3].
  • COVID-19: A clinical study was initiated to explore T89’s effects on improving oxygen saturation and clinical symptoms in COVID-19 patients[6].

Dosage and Administration

The dosage of T89 can vary depending on the condition being treated and the specific study protocol. Some common dosages used in clinical trials include:

  • For chronic stable angina: 150mg to 300mg taken twice daily[4].
  • For acute mountain sickness prevention: 225mg to 300mg taken twice daily for several days before and during ascent to high altitudes[5].
  • For COVID-19 treatment: 300mg taken three times daily for up to 14 days[6].

It’s important to note that these dosages are based on clinical trials, and the appropriate dosage for an individual patient should be determined by a healthcare provider.

Potential Side Effects and Safety

T89 has been used in China and other countries for many years, with over 2 billion doses prescribed to about 10 million people[1]. While this suggests a generally good safety profile, all medications can have potential side effects. Clinical trials have been conducted to assess the safety and tolerability of T89, including studies in healthy Japanese volunteers[2].

As with any medication, patients should report any unusual symptoms or side effects to their healthcare provider. Additionally, T89 may interact with other medications, so it’s important to inform your doctor about all drugs and supplements you are taking.

Future Research and Potential Uses

Ongoing research is exploring additional potential uses for T89:

  • COVID-19 treatment: Further studies may investigate T89’s role in managing COVID-19 symptoms and improving outcomes[7].
  • Drug interactions: Research is being conducted to understand how T89 may interact with other medications, particularly those metabolized by certain liver enzymes[8].

As research continues, our understanding of T89’s benefits and potential applications may expand, potentially leading to new treatment options for patients with various cardiovascular and respiratory conditions.

Aspect Details
Drug Composition Extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol
Main Conditions Studied Chronic stable angina, Acute mountain sickness (AMS), COVID-19
Key Mechanisms Improves oxygen carrying capacity, increases oxygen saturation, reduces organ injury from hypoxia
Administration Oral capsules, typically 150-300mg once or twice daily
Primary Outcomes Measured Exercise duration (angina), LLSS scores (AMS), oxygen saturation levels, clinical symptoms
Safety Assessment Monitoring of adverse events and serious adverse events in all trials
Trial Phases Phase II and III studies ongoing
Notable Features Derived from traditional Chinese medicine, being studied for diverse conditions

FAQ

  • What is T89 and what conditions is it being studied for? T89 is a botanical drug derived from traditional Chinese medicine, containing extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol. It is being studied for chronic stable angina, acute mountain sickness (AMS), and COVID-19.
  • How does T89 work? T89 has effects of activating blood circulation, removing blood stasis, regulating Qi, and relieving pain. It can improve oxygen carrying capacity of red blood cells, increase oxygen saturation, and reduce organ injury caused by hypoxia.
  • What are the main outcomes being measured in T89 clinical trials? The main outcomes include changes in exercise duration for angina patients, Lake Louise Scoring System (LLSS) scores for AMS, oxygen saturation levels, and various clinical symptoms depending on the condition being studied.
  • Are there any side effects associated with T89? The clinical trials are designed to assess the safety profile of T89. So far, the studies monitor for adverse events, but specific side effects have not been prominently mentioned in the trial descriptions.
  • How is T89 administered in these clinical trials? T89 is typically administered orally in capsule form. The dosage and frequency vary depending on the condition and specific trial, ranging from 150mg to 300mg, taken once or twice daily.

Ongoing Clinical Trials on T89

  • Study on the Effects of T89 and Glyceryl Trinitrate for Patients with Stable Angina

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Poland Romania Slovakia

Glossary

  • Acute Mountain Sickness (AMS): A condition that can occur when ascending to high altitudes too quickly, characterized by symptoms such as headache, nausea, dizziness, and fatigue.
  • Angina Pectoris: Chest pain or discomfort caused by reduced blood flow to the heart, often described as a squeezing or pressure sensation.
  • Botanical Drug: A medicinal product derived from plants or plant extracts, used to diagnose, treat, or prevent disease.
  • Chronic Stable Angina: A type of chest pain that occurs predictably with physical exertion or emotional stress, caused by narrowed coronary arteries.
  • COVID-19: An infectious disease caused by the SARS-CoV-2 virus, which can lead to respiratory symptoms and other health complications.
  • Exercise Tolerance Test (ETT): A medical test that involves exercising on a treadmill or stationary bike while being monitored to evaluate heart function and exercise capacity.
  • Hypoxia: A condition in which the body or a region of the body is deprived of adequate oxygen supply at the tissue level.
  • Lake Louise Scoring System (LLSS): A standardized method used to assess the presence and severity of acute mountain sickness symptoms.
  • Oxygen Saturation: The percentage of hemoglobin binding sites in the bloodstream occupied by oxygen, typically measured using a pulse oximeter.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the drug being tested.

References

  1. https://clinicaltrials.gov/study/NCT00797953
  2. https://clinicaltrials.gov/study/NCT01679028
  3. https://clinicaltrials.gov/study/NCT03552263
  4. https://clinicaltrials.eu/trial/study-on-the-effects-of-t89-and-glyceryl-trinitrate-for-patients-with-stable-angina/
  5. https://clinicaltrials.gov/study/NCT04993729
  6. https://clinicaltrials.gov/study/NCT04285190
  7. https://clinicaltrials.gov/study/NCT04646031
  8. https://clinicaltrials.gov/study/NCT01473888